Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): Results of a dose-finding study in rheumatoid arthritis

Journal of Rheumatology

Volumn 30, Issue 10, 2003, Pages 2123-2126

  Furst, Daniel E ^a   Weisman, Michael ^b,c   Paulus, Harold E ^a   Bulpitt, Kenneth ^a   Weinblatt, Michael ^f   Polisson, Richard ^f   Zaug, Michel ^d   Kneer, Johannes ^d   Van Der Auwera, Philippe ^d   Stevens, Randall M ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e HOFFMANN LA ROCHE INC   (United States)

^f NONE

Author keywords

Controlled trial; Phase II; Rheumatoid arthritis; Tumor necrosis factor receptor

Indexed keywords

ETANERCEPT; LENERCEPT; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT TUMOR NECROSIS FACTOR;

ADULT; AGED; ANALGESIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIBODIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN GAMMA-CHAINS; IMMUNOGLOBULIN HEAVY CHAINS; INFUSIONS, INTRAVENOUS; JOINTS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10744225052     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Choy EHS, Panai GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
3. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
4. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
5. Lipsky PE, van der Heijde D, St Clair W, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
6. den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002;29:2288-98.
7. van de Putte LBA, Atkins C, Malaise M, et al. Adalimumab (D2E7) monotherapy in the treatment of patients with severely active rheumatoid arthritis [abstract]. Arthritis Rheum 2002;46 Suppl:S205.
8. Keystone E, Kavanaugh AF, Sharp J, et al. Adalimumab (D2E7), a fully human anti-TNF-alpha monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [abstract]. Arthritis Rheum 2002;46 Suppl:S205.
9. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
10. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
11. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
12. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
13. Hasler F, van de Putte L, Dumont E, et al. Safety and efficacy of TNF neutralization by lenercept in patients with rheumatoid arthritis exposed to a single dose [abstract]. Arthritis Rheum 1996;39 Suppl:S243.
14. Furst D, Weisman M, Paulus H, et al. Neutralization of TNF by lenercept (TNFR 55 TgGt, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: Results of a phase II trial [abstract]. Arthritis Rheum 1996;39 Suppl:S243.
15. Rau R, Sander O, van Riel P, et al. Intravenous human recombinant TNF receptor p55-Fc IgG1 fusion protein, Ro 45-2081: Double-blind, placebo-controlled dose finding study in long-standing, active rheumatoid arthritis. J Rheumatol 2003;30:680-90.